BioCentury
ARTICLE | Clinical News

Seaside's STX209 misses in Phase IIb trial for autism

May 2, 2013 1:35 AM UTC

Seaside Therapeutics Inc. (Cambridge, Mass.) said oral STX209 for 12 weeks missed the primary endpoint vs. placebo in the Phase IIb Study 209AS208 to treat autism spectrum disorders (ASD). Specifically, STX209 missed the primary endpoint of reducing patient-rated Aberrant Behavior Checklist-Social Withdrawal (ABC-SW) subscale scores from baseline to week eight vs. placebo (5.4 vs. 6 points, p=0.518). The double-blind, U.S. trial enrolled 150 patients ages 5 to 21 years with ASD. Data will be presented on Thursday at the International Meeting for Autism Research in San Sebastian. Seaside said it plans to confirm the results by initiating another controlled trial of STX209 in patients with ASD, but did not disclose details. ...